Novel Hydrophilic Taxane Analogues inhibit Growth of Cancer Cells

  • Fauzee, Nilufer Jasmine Selimah (Department of Pathology, Molecular Medicine and Cancer Research Center, Chongqing Medical University) ;
  • Wang, Ya-Lan (Department of Pathology, Molecular Medicine and Cancer Research Center, Chongqing Medical University) ;
  • Dong, Zhi (Department of Pharmacology, Pharmacy College, Chongqing Medical University) ;
  • Li, Qian-Ge (Department of Pharmacology, Pharmacy College, Chongqing Medical University) ;
  • Wang, Tao (Department of Pharmacology, Pharmacy College, Chongqing Medical University) ;
  • Mandarry, Muhammad Tasleem (Department of General Surgery, The First Affiliated Hospital of Chongqing Medical University) ;
  • Lu, Xu (Department of Pharmacology, Pharmacy College, Chongqing Medical University) ;
  • Juan, Pan (Department of Pathology, Molecular Medicine and Cancer Research Center, Chongqing Medical University)
  • Published : 2012.02.29


In our era there has been several anti-cancer drugs which have undergone both experimental and clinical trials; however, due to their poor solubilities, numerous side effects, insufficient bioavailability and poor compliance, many have resulted into poor outcomes. Therefore, our aim was to investigate the effects of novel hydrophilic taxanes analogues CQMU-0517 and CQMU-0519 on growth of A549 lung, SKVO3 ovary and MCF7 breast carcinoma cell lines. Different concentrations of original paclitaxel, CQMU-0517, original docetaxel and CQMU-0519 were utilized on three cell lines, where cell growth was assessed using cell culture kit-8 and flow cytometry analysis. The results unveiled that CQMU-0517 and CQMU-0519 suppressed cell growth in the three particular cell lines, cell cycle arrest being evident in the G2/M phase. Hence, the results showed that these new taxane analogues have potential and warrant future clinical trials.




  1. Bissery MC, Guenard D, Gueritte-Voegelein F, et al (1991). Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res, 51, 4845-52.
  2. Calderoni A, Cerny T (2001). Taxanes in lung cancer: a review with focus on the European experience. Crit Rev Oncol Hematol, 38, 105-27.
  3. Chang JT, Chang GC, Jiunn-Liang Ko, et al (2006). Induction of tubulin by Docetaxel is associated with p53 status in,human non small cell lung cancer cell lines. Int J Cancer, 118, 317-25.
  4. Derry WB, Wilson L, Jordan MA (1995). Substoichiometric binding of taxol suppresses microtubule dynamics. Biochem, 34, 2203-11.
  5. Fabbri F, Carloni S, Brigliadori G, et al (2006). Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biol, 7, 6.
  6. Fauzee NJS, Dong Z, Wang YL (2011). Taxanes: promising anti-cancer drugs. Asian Pac J Cancer Prev, 12, 837-51
  7. Ferlini C, Di Stefano M, Marone M, et al (1998). The synergistic anti-tumour activity of ICI 182,780 in combination with docetaxel is mediated by P-glycoprotein inhibition. Endocr Relat Canc, 5, 315-24.
  8. Geng CX, Zeng ZC, Wang JY (2003). Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol, 9, 696-700.
  9. Grant DS, Williams TL, Zahaczewsky M, et al (2003). Comparison of antiangiogenic activities using Paclitaxel (TAXOL) and Docetaxel (TAXOTERE). Int J Cancer, 104, 121-9.
  10. Hennenfent KL, Govindan R (2006). Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol, 17, 735-49.
  11. Ichite N, Chougule MB, Jackson T, et al (2009). Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res, 15, 543-52.
  12. Jordan MA, Toso RJ, Thrower D, et al (1993). Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A, 90, 9552-6.
  13. Jordan MA, Wendell K, Gardiner S et al (1996). Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res, 56, 816-25.
  14. Jordan MA, Wilson L (1998). Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol, 10, 123-30.
  15. Kang J, Wu X, Wang Z, et al (2010). Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. J Ultrasound Med, 29, 61-70.
  16. Katopodis O, Polyzos A, Kentepozidis N, et al (2010). Second line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmaco, 67, 361-8.
  17. Liebmann JE, Cook JA, Lipschultz C et al (1993). Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer, 68, 1104-9.
  18. Maenpaa JU(2003). Docetaxel: promising and novel combinations in ovarian cancer. Br J Cancer, 89, S29-34.
  19. Mahaffey CM, Davies AM, Lara PN Jr, et al (2007). Schedule dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer, 8, 548-53.
  20. Mhaidat NM, Zhang XD, ChenJiang C, et al (2007). Docetaxelinduced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signalregulated kinase 1/2 pathway. Clin Cancer Res, 13, 1308-14.
  21. Mhaidat NM, Wang Y, Kiejda KA, et al (2007). Docetaxelinduced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther, 6, 752-61.
  22. Nabell L, Spencer S (2003). Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol, 30, 89-93.
  23. Nehme A, Varadarajan P, Sellakumar G, et al (2001). Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. Br J Cancer, 84, 1571-6.
  24. Pectasides D, Pectasides M, Farmakis D, et al (2005). Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol, 16, 294-9.
  25. Rao S, He L, Chakravarty S, et al (1999). Characterization of the taxol binding site on the microtubule. Identification of Arg282 in b-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol. J Biol Chem, 274, 37990-4.
  26. Schiff PB, Fant J, Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-7.
  27. Schiff PB, Horwitz SB (1980). Taxol stabilizes microtubules in mouse fibroblast cells. PNAS, 77, 1561-5.
  28. Snyder JP, Nettles JH, Cornett B, et al (2001). The binding conformation of Taxol in b-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci U S A, 98, 5312-6.
  29. Wani MC, Taylor HL, Wall ME, et al (1971). Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J AM Chem Soc, 93, 2325-7.
  30. Wang QW, Lu HL, Song CC, et al (2005). Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel. World J Gastroenterol, 11, 4003-7.
  31. Wang Z, Li M, Zhao W, Zhao G, et al (2007). Establishment and characterization of lung adenocarcinoma cell lines with multidrug resistance. Life Sci J, 4, 13-6.
  32. Wenzel C, Steger GG (2006). Adjuvant treatment of breast cancer with taxanes. Breast Care, 1, 171-5.
  33. Yvon AM, Wadsworth P, Jordan MA (1999). Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell, 10, 947-59.

Cited by

  1. Protective Role of Aspirin, Vitamin C, and Zinc and their Effects on Zinc Status in the DMH-Induced Colon Carcinoma Model vol.14, pp.8, 2013,